文献速递淋巴瘤

未编辑的自体CD5.CAR T细胞治疗复发/难治性成熟T细胞淋巴瘤的抗肿瘤疗效与安全性

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas.
PubMed 文献 · Blood · 2024-01-01

本研究为首次人体1期试验(NCT0308190),评估第二代自体CD5.CAR T细胞治疗复发/难治性成熟T细胞淋巴瘤的安全性和疗效。17例入组患者中,14次尝试制备有13次成功(93%),9例(69%)接受输注;总缓解率为44%,2例完全缓解。最常见的≥3级不良事件为血细胞减少,未发生≥3级细胞因子释放综合征或神经事件。

要点

  • CD5.CAR T细胞在17例复发/难治性成熟T细胞淋巴瘤患者中,14次制备尝试成功13次(93%),9例(69%)接受输注。
  • 总缓解率为44%,其中2例达完全缓解。
  • 最常见≥3级不良事件为血细胞减少,未发生≥3级细胞因子释放综合征或神经事件。

核心结论

  • CD5.CAR T细胞在复发/难治性CD5表达T细胞淋巴瘤患者中安全,并可诱导临床缓解,且未消除内源性T细胞或增加感染并发症。
  • 需要更多患者和更长随访进行验证。

研究设计与样本

  • 首次人体1期研究(NCT0308190),采用第二代自体CD5.CAR T细胞治疗复发/难治性T细胞恶性肿瘤,本文报告成熟T细胞淋巴瘤队列的安全性和疗效数据。
  • 17例成熟T细胞淋巴瘤患者入组,14次制备尝试中13次成功(93%),9例(69%)接受输注。

主要发现

  • 总缓解率(完全缓解或部分缓解)为44%,其中2例观察到完全缓解。
  • 最常见的≥3级不良事件为血细胞减少。
  • 未发生≥3级细胞因子释放综合征或神经事件。
  • 2例患者在即时毒性评估期内因疾病快速进展死亡。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更多患者和更长随访进行验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite newer targeted therapies, patients with primary refractory or relapsed (r/r) T-cell lymphoma have a poor prognosis. The development of chimeric antigen receptor (CAR) T-cell platforms to treat T-cell malignancies often requires additional gene modifications to overcome fratricide because of shared T-cell antigens on normal and malignant T cells. We developed a CD5-directed CAR that produces minimal fratricide by downmodulating CD5 protein levels in transduced T cells while retaining strong cytotoxicity against CD5+ malignant cells. In our first-in-human phase 1 study (NCT0308190), second-generation autologous CD5.CAR T cells were manufactured from patients with r/r T-cell malignancies. Here, we report safety and efficacy data from a cohort of patients with mature T-cell lymphoma (TCL). Among the 17 patients with TCL enrolled, CD5 CAR T cells were successfully manufactured for 13 out of 14 attempted lines (93%) and administered to 9 (69%) patients. The overall response rate (complete remission or partial response) was 44%, with complete responses observed in 2 patients. The most common grade 3 or higher adverse events were cytopenias. No grade 3 or higher cytokine release syndrome or neurologic events occurred. Two patients died during the immediate toxicity evaluation period due to rapidly progressive disease. These results demonstrated that CD5.CAR T cells are safe and can induce clinical responses in patients with r/r CD5-expressing TCLs without eliminating endogenous T cells or increasing infectious complications. More patients and longer follow-up are needed for validation. This trial was registered at www.clinicaltrials.gov as #NCT0308190.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hill LC, Rouce RH, Wu MJ, et al. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024. PMID: 38145560. doi:10.1182/blood.2023022204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。